In his new book, former NIMH director Thomas Insel, while exploring the causes of poor mental health outcomes in the United States, omits any mention of NIMH studies that tell of how the drugs worsen long-term outcomes.
Insel says he has the answer—the same emphasis on neuroscience and genetics, which he admits led to no improvements under his leadership at NIMH.
Dr. Thomas Insel worked as the director of the NIMH for thirteen years, and now he is moving on to Google where he hopes to help develop technology to monitor our mental health.
Google has hired the former director of the National Institute of Mental Health (NIMH), Thomas Insel, with plans to create “a wearable sensor to measure mood, cognition and anxiety.” Gizmodo points out the problems with this idea:“One can easily imagine a message popping up on some poor desk jockey’s monitor: ‘You’re not in the right mood today. Please take a day of unpaid leave.’ Or, worse: ‘We’ve detected signs of mental instability, based on how you’ve been talking and sleeping. Please report to a doctor immediately.’”
Neuroskeptic weighs in on the controversy over the lack of antipsychotic dose data in the RAISE study and the misleading media coverage. He points out that one of the treatment interventions was a computerized medication management system called COMPASS, which recommends doctors use lower doses than they otherwise might.
Yesterday, the New York Times reported that schizophrenia patients in an experimental treatment program (RAISE) who experienced better outcomes had been on lower doses of antipsychotics than normal. However, the article published in the American Journal of Psychiatry on Tuesday did not divulge any data on the varying antipsychotic drug doses in the different study groups.